Researchers assess the link between year-to-year blood pressure variability at different life stages and the risk of developing dementia.
ASCO 2024: J&J’s early radioligand prostate cancer trial reports four patient deaths – Pharmaceutical Technology
J&J’s asset works by delivering an actinium-based radioligand which emits high-energy short-range alpha particles. Image credit: Shutterstock/Jurik Peter. Johnson & Johnson’s (J&J) prostate cancer radiotherapy